210 related articles for article (PubMed ID: 37503694)
21. Prognostic value of metabolic tumor volume of pretreatment
Kumasaka S; Nakajima T; Arisaka Y; Tokue A; Achmad A; Fukushima Y; Shimizu K; Kaira K; Higuchi T; Tsushima Y
BMC Med Imaging; 2018 Nov; 18(1):46. PubMed ID: 30477476
[TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of metabolic tumor volume and total lesion glycolysis in patients with advanced cervical carcinoma.
Calles-Sastre L; Mucientes-Rasilla J; San-Frutos Llorente LM; Royuela A; Garcia-Espantaleón Navas M; Herrero Gámiz S; Pérez-Medina T
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(1):17-21. PubMed ID: 30366731
[TBL] [Abstract][Full Text] [Related]
23. Volumetric PET parameters can predict overall survival in advanced lung adenocarcinoma.
Yanarateş A; Yazici B
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(1):3-8. PubMed ID: 31818695
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of baseline
Xia L; Li X; Zhu J; Gao Z; Zhang J; Yang G; Wang Z
Radiat Oncol; 2023 Feb; 18(1):41. PubMed ID: 36829219
[TBL] [Abstract][Full Text] [Related]
25. The correlation of
Qu YH; Long N; Ran C; Sun J
Clin Transl Oncol; 2021 Mar; 23(3):620-627. PubMed ID: 32683540
[TBL] [Abstract][Full Text] [Related]
26.
Wu X; Huang Y; Li Y; Wang Q; Wang H; Jiang L
Ann Nucl Med; 2019 Sep; 33(9):647-656. PubMed ID: 31165974
[TBL] [Abstract][Full Text] [Related]
27. Relationship between Overall Survival of Patients with Non-Small Cell Lung Cancer and Whole-Body Metabolic Tumor Burden Seen on Postsurgical Fluorodeoxyglucose PET Images.
Zhang C; Liao C; Penney BC; Appelbaum DE; Simon CA; Pu Y
Radiology; 2015 Jun; 275(3):862-9. PubMed ID: 25584710
[TBL] [Abstract][Full Text] [Related]
28. Predictive and Prognostic Role of Metabolic Response in Patients With Stage III NSCLC Treated With Neoadjuvant Chemotherapy.
Castello A; Toschi L; Rossi S; Finocchiaro G; Grizzi F; Mazziotti E; Qehajaj D; Rahal D; Lopci E
Clin Lung Cancer; 2020 Jan; 21(1):28-36. PubMed ID: 31409523
[TBL] [Abstract][Full Text] [Related]
29. Primary tumor standardized uptake value (SUVmax) measured on
Hui Z; Wei F; Ren H; Xu W; Ren X
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2595-2605. PubMed ID: 32494919
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of total tumour volume, adding necrosis to metabolic tumour volume, in advanced or metastatic non-small cell lung cancer treated with first-line pembrolizumab.
Eude F; Guisier F; Salaün M; Thiberville L; Pressat-Laffouilhere T; Vera P; Decazes P
Ann Nucl Med; 2022 Mar; 36(3):224-234. PubMed ID: 35060071
[TBL] [Abstract][Full Text] [Related]
31. The utility of
Kitajima K; Kawanaka Y; Komoto H; Minami T; Yokoi T; Kuribayashi K; Kijima T; Nakamura A; Hashimoto M; Kondo N; Hasegawa S; Yamakado K
Hell J Nucl Med; 2021; 24(3):186-198. PubMed ID: 34901959
[TBL] [Abstract][Full Text] [Related]
32.
Peng L; Du B; Cui Y; Luan Q; Li Y; Li X
Clin Lung Cancer; 2022 Nov; 23(7):608-619. PubMed ID: 36089482
[TBL] [Abstract][Full Text] [Related]
33. Prognostic Value of Metabolic Parameters of Metastatic Lymph Nodes on
Jin F; Qu B; Fu Z; Zhang Y; Han A; Kong L; Yu J
Clin Lung Cancer; 2018 Jan; 19(1):e101-e108. PubMed ID: 28690012
[TBL] [Abstract][Full Text] [Related]
34. FDG-PET biomarkers associated with long-term benefit from first-line immunotherapy in patients with advanced non-small cell lung cancer.
Seban RD; Assie JB; Giroux-Leprieur E; Massiani MA; Soussan M; Bonardel G; Chouaid C; Playe M; Goldfarb L; Duchemann B; Girard N; Champion L
Ann Nucl Med; 2020 Dec; 34(12):968-974. PubMed ID: 33070295
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.
Chen HH; Chiu NT; Su WC; Guo HR; Lee BF
Radiology; 2012 Aug; 264(2):559-66. PubMed ID: 22692034
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Value of Metabolic and Volumetric Parameters of Preoperative FDG-PET/CT in Patients With Resectable Pancreatic Cancer.
Im HJ; Oo S; Jung W; Jang JY; Kim SW; Cheon GJ; Kang KW; Chung JK; Kim EE; Lee DS
Medicine (Baltimore); 2016 May; 95(19):e3686. PubMed ID: 27175707
[TBL] [Abstract][Full Text] [Related]
37.
Li Y; Wu X; Huang Y; Bian D; Jiang L
Ann Nucl Med; 2020 May; 34(5):314-321. PubMed ID: 32088884
[TBL] [Abstract][Full Text] [Related]
38. FDG PET/CT Tumor Dissemination Characteristic Predicts the Outcome of First-Line Systemic Therapy in Non-small Cell Lung Cancer.
Tan W; Zhang Y; Wang J; Zheng Z; Xing L; Sun X
Acad Radiol; 2023 Dec; 30(12):2904-2912. PubMed ID: 37202226
[TBL] [Abstract][Full Text] [Related]
39. Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab.
Dall'Olio FG; Calabrò D; Conci N; Argalia G; Marchese PV; Fabbri F; Fragomeno B; Ricci D; Fanti S; Ambrosini V; Ardizzoni A
Eur J Cancer; 2021 Jun; 150():99-107. PubMed ID: 33892411
[TBL] [Abstract][Full Text] [Related]
40. Metabolic parameters of [
Markus M; Sartor H; Bjurberg M; Trägårdh E
Acta Oncol; 2023 Feb; 62(2):180-188. PubMed ID: 36815676
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]